ABSTRACT
Levels of oxytocin [OXT] hormone and inflammatory biomarkers [leptin, resistin and adiponectin] were measured in 166 plasma samples of Metabolic Syndrome [MS] patients [1] that visited the outpatients' endocrinology clinics, Jordan University Hospital [JUH]. Patients were subdivided into two arms according to their glucose profile status, subjects with glucose profile disturbances and normoglycemic subjects. MS biomarkers were significantly different [P<0.01] between study groups, mean OXT levels [ng/mL] were exceptionally higher [p<0.01] in MS-control group [2.25+0.85] than in MS-pre/T2DM group [1.20+0.50]. Conversely, in comparison to MS-controls; MS-pre/T2DM patients had significantly higher adipocytokines plasma levels; namely resistin was 13 times higher [ng/mL] [82.05+ 32.44 vs. 6.45+4.39]; leptin two times higher [ng/mL] [42.43+30.44 vs. 22.76+14.19] and adiponectin was 3-fold higher [micro g/mL] [6.869+1.082 vs. 1.97+0.606]. These findings were indicative for the potential pharmacologic benefit of this hormone in minimization of inflammatory markers chronic deleterious effect
ABSTRACT
Oxytocin [OXT] is implicated as a novel therapy of obesity-diabetes. Nesfatin is an anorexigenic adipokine linked to improve insulin sensitivity and dysglycemia in obese/T2DM mice, while endothelin-1 [ET-1] is an endothelium vasoconstrictor that is dysregulated in metabolic insulin resistance. The aim of this study was to investigate OXT, ET-1, and nesfatin plasma levels and the correlation between these biomarkers and the various metabolic parameters in the human. In a cross-sectional study, MS-subjects attended the National Center for Diabetes Endocrinology and Genetics were enrolled based on their blood glucose levels into [82 MS-non-diabetic vs. 89 MS-pre/diabetic patients]. Plasma OXT, ET-1 and nesfatin levels were measured by competitive binding and sandwich enzyme-linked immunosorbent assays [ELISA]. When MS-pre/T2DM patients were compared to MS-controls, plasma OXT concentrations [pg/mL] were significantly lower [P < 0.001] [mean +/- SD; 1206.28 +/- 507.68 vs. 2224 +/- 871.22]; nesfatin plasma levels [ng/mL] were significantly higher [P < 0.01] [1.04 +/- 2.20 vs. 0.31 +/- 0.25]; while no differences were observed in ET-1 [pg/mL] plasma levels [P > 0.05] [4.21 +/- 4.19 vs. 4.01 +/- 3.51]. In conclusion, the present study is the first one which demonstrates an increase in nesfatin concentrations in MS-pre/diabetic patients vs. MS-non-diabetic. Our study reported a decrease in OXT levels in MS-pre/T2DM compared to MS-control. Besides, ET-1 concentrations had no significant difference between non-diabetic and diabetic-MS patients, serum OXT concentrations correlated with several clinical parameters; this is suggestive of OXT as a pharmacologic agent that opposes weight gain and improves insulin resistance